Favourable Results of Patritumab Deruxtecan in Patients with Leptomeningeal Metastatic Disease of Solid Tumours By Ogkologos - July 21, 2025 348 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the TUXEDO-3 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Advancing Cancer Prevention: A Conversation with NCI’s Dr. Philip Castle July 20, 2021 New on NCI’s Websites for December 2023 December 28, 2023 Foodie Friday: Couscous Salad August 13, 2021 Feeding the Gut July 14, 2023 Load more HOT NEWS Should Surgery And Radiation Be The Standard Treatment For DCIS? The... Pursuing precision medicine in a flagship lung cancer trial Cancer in My Community: Advancements in Cancer Care in Singapore Signal of Increased Risk of Major Cardiovascular Events and Cancer with...
